NPI: 1124105762 · HOOVER, AL 35244 · Pediatrics Physician · NPI assigned 11/01/2006
Authorized official WALTON, DAWN controls 19+ related entities in our dataset. Read more
| Authorized Official | WALTON, DAWN (CFO) |
| Parent Organization | THE CHILDREN'S HOSPITAL OF ALABAMA |
| NPI Enumeration Date | 11/01/2006 |
Other providers sharing the same authorized official: WALTON, DAWN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 43,903 | $2.38M |
| 2019 | 53,163 | $2.29M |
| 2020 | 43,476 | $1.89M |
| 2021 | 64,776 | $2.87M |
| 2022 | 65,036 | $2.88M |
| 2023 | 58,274 | $2.66M |
| 2024 | 53,480 | $2.74M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 80,562 | 74,212 | $5.46M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34,084 | 31,839 | $3.32M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 15,621 | 15,356 | $1.20M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 12,244 | 12,071 | $930K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 10,305 | 10,120 | $796K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 18,301 | 17,562 | $755K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 13,449 | 12,975 | $610K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 7,912 | 7,817 | $576K |
| 90670 | 8,873 | 8,721 | $489K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4,524 | 4,445 | $387K |
| 90698 | 9,574 | 9,440 | $305K | |
| 90461 | 4,399 | 4,365 | $271K | |
| 90680 | 6,530 | 6,461 | $243K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 18,496 | 17,846 | $223K |
| 90651 | 1,599 | 1,577 | $220K | |
| 90686 | 11,365 | 11,169 | $216K | |
| 90710 | 1,764 | 1,717 | $141K | |
| 87070 | 14,246 | 13,806 | $134K | |
| 90677 | 1,681 | 1,663 | $121K | |
| 90716 | 1,488 | 1,469 | $107K | |
| 90633 | 3,758 | 3,676 | $90K | |
| 90671 | 1,139 | 1,126 | $78K | |
| 90744 | 3,609 | 3,543 | $76K | |
| 99173 | 19,424 | 18,899 | $75K | |
| 90734 | 870 | 848 | $74K | |
| 92551 | 16,594 | 16,162 | $71K | |
| 90707 | 1,421 | 1,408 | $69K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,181 | 3,045 | $65K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7,331 | 7,056 | $64K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1,531 | 1,525 | $46K |
| 96127 | 6,731 | 6,588 | $40K | |
| 90619 | 436 | 434 | $39K | |
| 90700 | 1,654 | 1,641 | $38K | |
| 90713 | 1,156 | 1,150 | $36K | |
| 87634 | 802 | 771 | $36K | |
| 90685 | 1,647 | 1,627 | $32K | |
| 99051 | 1,564 | 1,506 | $31K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2,642 | 2,572 | $30K |
| 80061 | Lipid panel | 1,859 | 1,725 | $23K |
| 90656 | 1,130 | 1,120 | $22K | |
| 99177 | 936 | 926 | $19K | |
| 90715 | 604 | 591 | $17K | |
| 99215 | Prolong outpt/office vis | 151 | 146 | $17K |
| 36416 | 14,082 | 12,674 | $14K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 129 | 111 | $10K |
| 90696 | 262 | 258 | $10K | |
| 90648 | 929 | 923 | $10K | |
| 83655 | 665 | 637 | $9K | |
| 0072A | 200 | 200 | $8K | |
| 99381 | 96 | 95 | $6K | |
| 0001A | 182 | 180 | $6K | |
| 0071A | 185 | 185 | $6K | |
| G0444 | Annual depression screening, 5 to 15 minutes | 226 | 224 | $5K |
| 0002A | 147 | 147 | $5K | |
| 36415 | Collection of venous blood by venipuncture | 1,424 | 1,365 | $4K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 147 | 134 | $3K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 31 | 21 | $3K |
| 90672 | 138 | 136 | $3K | |
| 99461 | 28 | 27 | $2K | |
| 81003 | 865 | 812 | $2K | |
| 99383 | 27 | 25 | $1K | |
| 69210 | 41 | 26 | $1K | |
| 99000 | 916 | 884 | $949.67 | |
| 90660 | 29 | 29 | $725.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 70 | 66 | $616.42 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 37 | 37 | $573.78 |
| 0081A | 13 | 13 | $480.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 351 | 342 | $447.42 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 57 | 52 | $438.36 |
| 94760 | 1,199 | 1,124 | $433.94 | |
| 96380 | 17 | 17 | $416.56 | |
| 99401 | 16 | 14 | $307.08 | |
| 96161 | 72 | 71 | $227.47 | |
| 85013 | 60 | 57 | $160.46 | |
| 92558 | 13 | 13 | $142.68 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 13 | 13 | $4.94 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 271 | 255 | $0.00 |
| 99080 | 1,983 | 1,880 | $0.00 |